A Randomized, Placebo-Controlled Study Of Liraglutide 3Mg Daily (Saxenda®) In Obese Or Overweight Patients With Stable Bipolar Disorder
Posted Date: Jun 12, 2019
- Investigator: Susan Lynn Mcelroy
- Specialties: Bipolar Disorder, Psychiatry/Psychology
- Type of Study: Drug
The purpose of this research study is to explore if Liraglutide treatment will reduce body weight and improve metabolic health in obese or overweight patients with Stable Bipolar Disorder without worsening their psychiatric symptoms. Liraglutide is approved in along with exercise and reducing caloric intake as a treatment option for chronic weight management in individuals with obesity. You will be in the research study for up to 45 weeks. The research study begins with a 2 to 4 week screening period, followed by a 40-week treatment period and concludes with a final follow up visit. You will be "randomized" to receive either the investigational medication (Liraglutide 3 milligrams per day by an under the skin injection) or placebo (injection with no active medication). Randomization means that you are put into a group completely by chance. It is like flipping a coin. Participants receive $50 for each completed visit. An online, pre-screen questionnaire can be completed at www.LCOH.info to see if you qualify.
Criteria:
Age 18-65 And Have Stable Bipolar Disorder On A Consistent Medication Schedule. Participants Must Also Be Obese Or Overweight.
Keywords:
Bipolar, Obese, Overweight
For More Information:
Anna Guerdjikova
513-536-0710
anna.guerdjikova@lindnercenter.org